These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

137 related articles for article (PubMed ID: 10225537)

  • 1. Specific COX-2 inhibitors in arthritis, oncology, and beyond: where is the science headed?
    Lipsky PE
    J Rheumatol Suppl; 1999 Apr; 56():25-30. PubMed ID: 10225537
    [TBL] [Abstract][Full Text] [Related]  

  • 2. COX-2, NSAIDs and human neoplasia. Part I: Colorectal neoplasms.
    Nasir A; Fernandez PM; Chughtai OR; Kaiser HE
    In Vivo; 2002; 16(6):501-9. PubMed ID: 12494894
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Biological functions of cyclooxygenase 2: control of its expression and activity].
    Jacquemin C
    J Soc Biol; 2000; 194(3-4):189-93. PubMed ID: 11324321
    [TBL] [Abstract][Full Text] [Related]  

  • 4. COX-1 and COX-2 in health and disease.
    Adelizzi RA
    J Am Osteopath Assoc; 1999 Nov; 99(11 Suppl):S7-12. PubMed ID: 10643175
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Cyclooxygenase 2: from inflammation to carcinogenesis.
    Ristimäki A
    Novartis Found Symp; 2004; 256():215-21; discussion 221-6, 259-69. PubMed ID: 15027493
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Rofecoxib [Vioxx, MK-0966; 4-(4'-methylsulfonylphenyl)-3-phenyl-2-(5H)-furanone]: a potent and orally active cyclooxygenase-2 inhibitor. Pharmacological and biochemical profiles.
    Chan CC; Boyce S; Brideau C; Charleson S; Cromlish W; Ethier D; Evans J; Ford-Hutchinson AW; Forrest MJ; Gauthier JY; Gordon R; Gresser M; Guay J; Kargman S; Kennedy B; Leblanc Y; Leger S; Mancini J; O'Neill GP; Ouellet M; Patrick D; Percival MD; Perrier H; Prasit P; Rodger I
    J Pharmacol Exp Ther; 1999 Aug; 290(2):551-60. PubMed ID: 10411562
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The role of cyclooxygenases in inflammation, cancer, and development.
    Williams CS; Mann M; DuBois RN
    Oncogene; 1999 Dec; 18(55):7908-16. PubMed ID: 10630643
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Update on clinical developments with celecoxib, a new specific COX-2 inhibitor: what can we expect?
    Geis GS
    J Rheumatol Suppl; 1999 Apr; 56():31-6. PubMed ID: 10225538
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Suppression of intestinal polyps in Msh2-deficient and non-Msh2-deficient multiple intestinal neoplasia mice by a specific cyclooxygenase-2 inhibitor and by a dual cyclooxygenase-1/2 inhibitor.
    Lal G; Ash C; Hay K; Redston M; Kwong E; Hancock B; Mak T; Kargman S; Evans JF; Gallinger S
    Cancer Res; 2001 Aug; 61(16):6131-6. PubMed ID: 11507063
    [TBL] [Abstract][Full Text] [Related]  

  • 10. COX-2 inhibition and the control of pain.
    Kiefer W; Dannhardt G
    Curr Opin Investig Drugs; 2002 Sep; 3(9):1348-58. PubMed ID: 12498012
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Efficacy, safety and potential clinical roles of the COX-2-specific inhibitors.
    van der Bijl P; van der Bijl P
    Int J Immunopathol Pharmacol; 2003; 16(2 Suppl):17-22. PubMed ID: 14552700
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Regulation of cyclo-oxygenase-2.
    Stack E; DuBois RN
    Best Pract Res Clin Gastroenterol; 2001 Oct; 15(5):787-800. PubMed ID: 11566041
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Defining COX-2 inhibitors.
    Lipsky PE
    J Rheumatol Suppl; 2000 Oct; 60():13-6. PubMed ID: 11032097
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Cyclooxygenase-2 inhibitors in lung cancer.
    Ramalingam S; Belani CP
    Clin Lung Cancer; 2004 Jan; 5(4):245-53. PubMed ID: 14967078
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Clinical application of cyclooxygenase-2 inhibitors].
    Dzielska-Olczak M; Olczak S
    Pol Merkur Lekarski; 2001 Jun; 10(60):480-2. PubMed ID: 11503270
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Basic biology and clinical application of specific cyclooxygenase-2 inhibitors.
    Crofford LJ; Lipsky PE; Brooks P; Abramson SB; Simon LS; van de Putte LB
    Arthritis Rheum; 2000 Jan; 43(1):4-13. PubMed ID: 10643694
    [TBL] [Abstract][Full Text] [Related]  

  • 17. New insights into COX-2 biology and inhibition.
    Patrignani P; Tacconelli S; Sciulli MG; Capone ML
    Brain Res Brain Res Rev; 2005 Apr; 48(2):352-9. PubMed ID: 15850674
    [TBL] [Abstract][Full Text] [Related]  

  • 18. COX-1 and COX-2 tissue expression: implications and predictions.
    Crofford LJ
    J Rheumatol Suppl; 1997 Jul; 49():15-9. PubMed ID: 9249646
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Cyclooxygenase(COX)-2-inhibition in the prevention and treatment of colorectal carcinoma].
    Tuynman JB; Hulscher JB; Steller EP; van Lanschot JJ; Richel DJ
    Ned Tijdschr Geneeskd; 2003 Nov; 147(45):2207-12. PubMed ID: 14640057
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Cyclooxygenase-2 inhibition in colorectal cancer: boom or bust?
    Sanborn R; Blanke CD
    Semin Oncol; 2005 Feb; 32(1):69-75. PubMed ID: 15726508
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 7.